Découvrez nos professeurs et professeures!

Revenir au répertoire
Fiche précédente
Fiche suivante

Jean-Mathieu Beauregard

Médecin clinicien enseignant agrégé

Jean-Mathieu Beauregard
jean-mathieu.beauregard@fmed.ulaval.ca
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Oncologie

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer de l'appareil digestif
  • Cancer la prostate
  • Radiothérapie
  • Cancers hormonaux-dépendants

Projets de recherche

  • Enhancing the PARADIM platform to bridge the gap between data and AI in medical imaging - Société canadienne du cancer - Subventions de transformation de données sur le cancer, co-chercheur - 2024-09-01 au 2027-08-31
  • Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2022-04-01 au 2027-03-31
  • Screening of gastroenteropancreatic neuroendocrine tumors from patients for temozolomide-induced upregulation of SSTR2: Towards improved PRRT - Société des tumeurs Carcinoïdes-NeuroEndocrines du Canada, co-chercheur - 2023-04-01 au 2025-12-31
  • Potentiation of PRRT by chemotherapy-mediated upregulation of somatostatin receptor 2 in NET cell lines-derived tumors in mice and in Lung NET patient-derived tumor explants - Société des tumeurs Carcinoïdes-NeuroEndocrines du Canada, co-chercheur - 2022-04-01 au 2024-12-31
  • Théranostique personnalisée du cancer de la prostate - Fonds de recherche du Québec - Santé - Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, chercheur principal - 2022-07-01 au 2024-06-30
  • Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes - Ministère de la Santé et des Services sociaux, Fondation du CHU de Québec, Fondation Canadienne pour l'innovation (La) - Fonds des leaders John-R.-Evans (FLJR), chercheur principal - 2022-07-01 au 2023-12-15
  • National Program on Radioligand Therapy for Prostate Cancer - Cancer de la prostate Canada, BC Cancer Agency, co-chercheur - 2018-01-01 au 2022-12-31
  • Chemotherapy-induced upregulation of somatostatin receptors for enhancing therapeutic efficacy of, and eligibility to PRRT of neuroendocrine tumors - Société des tumeurs Carcinoïdes-NeuroEndocrines du Canada, co-chercheur - 2020-07-01 au 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée - Fonds de recherche du Québec - Santé - ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, Université de Sherbrooke, co-chercheur - 2018-04-01 au 2022-06-30

Publications

  • Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes., Laforce R, Bouchard RW, Verret L, Poulin S, Houde M, Fortin MP, Guimond J, Beauregard JM, Bergeron D, Journal of Alzheimer's disease : JAD, 2016, 10.3233/jad-150302
  • Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer., Hicks RJ, Roselt P, Degrado TR, Williams SG, Beauregard JM, Journal of medical imaging and radiation oncology, 2010, 10.1111/j.1754-9485.2010.02178.x
  • Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes., Celler A, Dewaraja YK, Beauregard JM, Gonzalez M, Uribe CF, Hou X, Esquinas PL, Zhao W, EJNMMI physics, 2018, 10.1186/s40658-018-0208-9
  • New developments in the imaging of metastatic prostate cancer., Pouliot F, Beauregard JM, Current opinion in supportive and palliative care, 2014, 10.1097/spc.0000000000000076
  • High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications., Hicks RJ, Bouvard G, Bardet S, Agostini D, Neels O, Roselt P, Kinross K, Beyer T, Beauregard JM, Desmonts C, Aide N, European journal of nuclear medicine and molecular imaging, 2010, 10.1007/s00259-009-1352-1
  • Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy., Pouliot F, Beauregard JM, Arsenault F, Current opinion in supportive and palliative care, 2018, 10.1097/spc.0000000000000357
  • Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study., Celler A, Beauregard JM, Hou X, Frezza A, Esquinas PL, Zhao W, Physics in medicine and biology, 2019, 10.1088/1361-6560/ab3039
  • Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma., Boockvar JA, Langer DJ, Beauregard JM, Asiry S, Anderson TA, Chakraborty S, Del Prete M, Buteau FA, Kulason KO, Tham TM, Scharf SC, Shatzkes DR, Schneider JR, Operative neurosurgery (Hagerstown, Md.), 2018, 10.1093/ons/opy028
  • Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction, Beauregard, J.-M., Després, P., Celler, A., Zhao, W., Uribe, C., Desport, C., Frezza, A., EJNMMI Physics, 2020, 10.1186/s40658-020-0275-6
  • Effective specific activities determined by scintillation proximity counting for production runs of [(18)F]FES and 4F-M[(18)F]FES., Bénard F, van Lier JE, Ouellette R, Ahmed N, Croteau E, Beauregard JM, Nuclear medicine and biology, 2007, 10.1016/j.nucmedbio.2007.01.001
  • Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT., Beauregard JM, Celler A, Buteau FA, Zhao W, Saighi N, Arsenault F, Del Prete M, EJNMMI physics, 2018, 10.1186/s40658-018-0224-9
  • Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer., Aide N, Zalcman G, Lemoel G, Gervais R, Bardet S, Guizard AV, Paciencia M, Milner A, Beauregard JM, Hicks RJ, Lasnon C, Clinical nuclear medicine, 2012, 10.1097/rlu.0b013e318251e3d1
  • Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor., Beauregard JM, Shah GM, Hoepfner M, Adant S, Shah RG, Purohit NK, Oncotarget, 2018, 10.18632/oncotarget.25266
  • Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study., Celler A, Beauregard JM, Gaudin E, Gonzalez M, Tanguay J, Esquinas PL, Uribe CF, EJNMMI physics, 2017, 10.1186/s40658-016-0170-3
  • FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., Pouliot F, Bouchard F, Rimac G, Tiguert R, Dujardin T, Lacombe L, Lemay C, Fradet Y, Caron A, Fradet V, Blouin AC, Beauregard JM, Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0
  • A CZT-based blood counter for quantitative molecular imaging., Després P, Beauregard JM, Lechippey L, Hamel LA, Martin JP, Frezza A, Espagnet R, EJNMMI physics, 2017, 10.1186/s40658-017-0184-5
  • Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale, Peter Bernhardt, Jean-Mathieu Beauregard, Tobias Rydén, Ida Marin, Linn Hagmarker, Johanna Svensson, Andreas Hallqvist, Biomedicines, 2021, 10.3390/biomedicines9111570
  • How we read FCH-PET/CT for prostate cancer., Beaulieu A, Beauregard JM, Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, 10.1186/s40644-016-0101-5
  • Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial., Beauregard JM, Beaulieu A, Bouchard LO, Saighi N, Arsenault F, Buteau FA, Del Prete M, European journal of nuclear medicine and molecular imaging, 2018, 10.1007/s00259-018-4209-7
  • Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions., Hicks RJ, Roselt P, Drummond E, Blum R, Aide N, Hofman MS, Giraudet AL, Beauregard JM, Nuclear medicine communications, 2013, 10.1097/mnm.0b013e3283606669
  • Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours., Beauregard JM, Shah GM, Adant S, European journal of nuclear medicine and molecular imaging, 2019, 10.1007/s00259-019-04499-x
  • 68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy., Hicks RJ, Eu P, Neels OC, Barber TW, Beauregard JM, Hofman MS, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, 10.2967/jnumed.111.093344
  • Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., Pouliot F, Fradet Y, Fradet V, Lacombe L, Nguile Makao M, Bergeron M, Beauregard JM, Morin F, European urology focus, 2017, 10.1016/j.euf.2017.02.007
  • Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT., Bénard F, van Lier JE, Ahmed N, Croteau E, Beauregard JM, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, 10.2967/jnumed.108.057000
  • GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome, Pouliot, F., Riopel, J., Buteau, F.-A., Beauregard, J.-M., Lacombe, D., Neveu, B., Champagne, A., Brisson, H., Bergeron, M., Lavallée, É., Lefebvre, V., Hovington, H., Ringuette Goulet, C., Meziou, S., Prostate Cancer and Prostatic Diseases, 2020, 10.1038/s41391-020-0202-x
  • An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging., Hicks RJ, Hogg A, Kron T, Hofman MS, Beauregard JM, Jackson PA, Medical physics, 2013, 10.1118/1.4824318
  • Steroid Receptor Imaging in Breast Cancer., Bénard F, Turcotte É, Beauregard JM, PET clinics, 2006, 10.1016/j.cpet.2005.09.006
  • Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations., Celler A, Beauregard JM, Zhao W, Hou X, Physics in medicine and biology, 2019, 10.1088/1361-6560/ab32a1
  • Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., Pouliot F, Beauregard JM, Fradet Y, Makao-Nguile M, Fradet V, Lacombe L, Tiguert R, Dujardin T, Duchesnay N, Blouin AC, Buteau FA, Bergeron M, Lavallée E, European urology focus, 2018, 10.1016/j.euf.2018.03.008
  • A dual radiologic contrast agent protocol for 18F-FDG and 18F-FLT PET/CT imaging of mice bearing abdominal tumors., Hicks RJ, Cullinane C, Dorow D, Roselt P, Potdevin T, Neels O, Beauregard JM, Kinross K, Aide N, Molecular imaging and biology, 2011, 10.1007/s11307-010-0378-x
  • [18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice., van Lier JE, Croteau E, Dubuc C, Aliaga A, Rousseau J, Beauregard JM, Ahmed N, Bénard F, European journal of nuclear medicine and molecular imaging, 2008, 10.1007/s00259-008-0745-x
  • The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy., Hicks RJ, Kong G, Hofman MS, Beauregard JM, European journal of nuclear medicine and molecular imaging, 2011, 10.1007/s00259-011-1937-3
  • Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers., Laforce R, Soucy JP, Bouchard RW, Houde M, Fortin MP, Verret L, Bergeron D, Guimond J, Buteau FA, Poulin S, Beauregard JM, Bensaïdane MR, Journal of Alzheimer's disease : JAD, 2016, 10.3233/jad-151180
  • Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas., Mac-Way F, Douville P, Couture F, Beauregard JM, Iliuta IA, Clinical nuclear medicine, 2015, 10.1097/rlu.0000000000000862
  • Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study., Beauregard JM, Buteau FA, Del Prete M, European journal of nuclear medicine and molecular imaging, 2017, 10.1007/s00259-017-3688-2
  • Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT, Beauregard, J.-M., Després, P., Frezza, A., Bouvet, G.F., Desy, A., EJNMMI Physics, 2020, 10.1186/s40658-020-00303-0
  • Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system., Hicks RJ, Eu P, Pereira JM, Hofman MS, Beauregard JM, Cancer imaging : the official publication of the International Cancer Imaging Society, 2011, 10.1102/1470-7330.2011.0012
  • Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells, Girish Shah, Jean-Mathieu Beauregard, Fayçal Zine-Eddine, Samuel Adant, Marine A. Merlin, Rashmi G. Shah, Cancers, 2021, 10.3390/cancers13020232
  • Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion., Hicks RJ, Zannino D, Beauregard JM, Eu P, Hofman MS, Jackson P, Kashyap R, European journal of nuclear medicine and molecular imaging, 2013, 10.1007/s00259-013-2504-x

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Sébastien Laberge - Maîtrise avec mémoire - En cours
  • Atefeh Zamanian - Doctorat - En cours
  • Hanieh Sadat Jozi - Doctorat - En cours
  • Marine Merlin - Doctorat - En cours
  • Vincent Forget - Maîtrise avec mémoire - En cours
  • Janyssa Charbonneau - Maîtrise avec mémoire - En cours
  • Mohammed Haron Obaid - Maîtrise avec mémoire - En cours
  • Jean-François Montégiani - Maîtrise avec mémoire - 2014/09
  • Emilie Gaudin - Maîtrise avec mémoire - 2015/05
  • Michela Del Prete - Doctorat - 2019/01
  • Andrea Frezza - Doctorat - 2021/01
  • Samuel Adant - Maîtrise avec mémoire - 2021/09
  • Alessandro Desy - Doctorat - 2024/01

Encadrement d'étudiant(e)s

Direction de recherche dans les domaines suivants :

  • Biologie cellulaire et moléculaire
  • Épidémiologie
  • Médecine moléculaire
  • Sciences cliniques et biomédicales

En savoir plus sur les programmes

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.
Mettre à jour mon profil de professeur(e)